Top Markets
Coin of the day
Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE
Clasificación en acciones #23495
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated... Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
Precio por acción
$19.30
Última sincronización: 2023-12-26
Capitalización bursátil
$72.77M
Cambio (1 día)
6.22%
Cambio (1 año)
0.00%
País
US
Comercio Aeglea BioTherapeutics, Inc. (AGLE)

Categoría

Historial del precio de la acción de Aeglea BioTherapeutics, Inc. (AGLE)
Precio más alto de cierre: $17.81 el 2023-12-01

Precio más bajo de cierre: $240.00 el 2016-04-01
Historial del precio de la acción de Aeglea BioTherapeutics, Inc. desde 2016 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2023 80.43%
2022 -90.79%
2021 -48.55%
2020 6.06%
2019 3.25%
2018 49.19%
2017 -3.90%
2016 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH